fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-01-25 Alizé Pharma (France)
Lilly (USA)
unacylated ghrelin (AZP-01) program
This program is focused on the development of unacylated ghrelin (UAG) agonists for the treatment of type II diabetes. UAG and its analogs have a therapeutic potential in diabetes through a novel mechanism of action that includes glucose and lipid-lowering effects, a trophic effect on beta cells, as well as insulin-sensitizing actions. / Type II diabetes
R&D
licensing
See details
2010-01-21 UCL Business plc (UK)
Institute for Child Health (University College London-UK)
Kurma Biofund (France)
intellectual property assets / childhood diseases other
See details
2010-01-21 b3 bio (USA)
Roche (Switzerland)
  R&D
licensing
other
See details
2010-01-21 Ipsen (France)
Inspiration Biopharmaceuticals (USA)
recombinant porcine factor VIII, OBI-1
recombinant factor IXproduct, IB1001
early-stage pipeline of additional hemophilia factors including recombinant factors VIIa and VIII) / hemophilia
R&D
licensing
development
marketing/ promotion
See details
2010-01-20 DiaGenic (Norway)
Ferrer inCode - subsidiary of Grupo Ferrer Internacional (Spain)
blood-based ADtect® test / Alzheimer’s disease commercialization/ distribution
See details
2010-01-19 Dako (Denmark)
AstraZeneca (UK)
companion diagnostics
/ cancer
R&D
development
See details
2010-01-19 Priaxon (Germany)
Boehringer Ingelheim (Germany)
mdm2/p53 inhibitors
p53 can be inactivated by the overexpression or amplification of MDM2 (murine double minute 2), which is the case in many p53 wild-type tumors. Thus, disruption of the MDM2–p53 interaction is considered a novel therapeutic strategy for cancer cells that still are endowed with wild-type p53, and a variety of small molecule drug like compounds have been reported that bind to the p53 binding site of MDM2.
/ cancer
R&D
licensing
See details
2010-01-19 GenVec (USA)
Novartis (Switzerland)
/ hearing loss and balance disorders R&D
licensing
See details
2010-01-19 Axxam (Italy)
Juvenile Diabetes Research Foundation (USA)
Fast Forward (USA)
compounds that can target specific ion channels in the immune system. / multiple sclerosis
type 1 diabetes.
R&D
other
See details
2010-01-14 Evotec (Germany)
CHDI Foundation (USA)
new treatments / Huntington’s disease R&D
See details
2010-01-14 Kenta Biotech (Switzerland)
Rentschler Biotechnologie (Germany)
KBSA301 antibody (fully human IgG antibody designed to treat infections caused by MRSA) / methicillin-resistant Staphylococcus aureus (MRSA) infections manufacturing
development
See details
2010-01-13 Kinaxo (Germany)
Roche Diagnostics (Switzerland)
phosphoproteomics platform PhosphoScout®
(The platform has been developed to investigate cellular signal transduction pathways and their response to drug treatment. It allows annotation and quantification of regulated phosphorylation sites in living cells, animal models and patient samples)
R&D
other
See details
2010-01-12 Cellectis (France)
Bayer HealthCare (Germany)
patent family WO9011354 covering homologous recombination aimed to introduce new features into the genome. licensing
other
See details
2010-01-12 Gentium (Italy)
Sigma-Tau Pharmaceuticals (Italy)
Defibrotide / veno-occlusive disease licensing
manufacturing
commercialization/ distribution
other
See details
2010-01-11 Sanofi Pasteur (France)
KaloBios (USA)
Humaneered™ antibody fragment / Pseudomonas aeruginosa infections
development
See details
[<<]      «      8   |   9   |   10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18      »      [65]